Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?

Currently there are no molecular biomarkers used to help guide treatment selection for those patients with castration-resistant prostate cancer. A recent study published in JAMA Oncology (Antonarakis et al.) presents evidence supporting the potential use of androgen receptor splice variant 7 as a bi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Biol Ther
Autors principals: Leibrand, Crystal R., Price, Douglas K., Figg, William D.
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2016
Matèries:
Journal Club
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4910935/
https://ncbi.nlm.nih.gov/pubmed/26985596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2016.1156274
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars